{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:06:41Z","timestamp":1790896001398,"version":"4.1.0"},"reference-count":351,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.jconrel.2010.11.033","type":"journal-article","created":{"date-parts":[[2010,12,5]],"date-time":"2010-12-05T09:15:36Z","timestamp":1291540536000},"page":"208-231","source":"Crossref","is-referenced-by-count":177,"title":["Neurotherapeutic applications of nanoparticles in Alzheimer's disease"],"prefix":"10.1016","volume":"152","author":[{"given":"Jasjeet Kaur","family":"Sahni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Doggui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjula","family":"Baboota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ramassamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9503","key":"10.1016\/j.jconrel.2010.11.033_bb0005","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)60607-8","article-title":"Alzheimer disease","volume":"42","author":"Smith","year":"1998","journal-title":"Int. Rev. Neurobiol."},{"issue":"6405","key":"10.1016\/j.jconrel.2010.11.033_bb0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/360672a0","article-title":"Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production","volume":"360","author":"Citron","year":"1992","journal-title":"Nature"},{"issue":"6534","key":"10.1016\/j.jconrel.2010.11.033_bb0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","article-title":"St George-Hyslop PH. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease","volume":"375","author":"Sherrington","year":"1995","journal-title":"Nature"},{"issue":"6543","key":"10.1016\/j.jconrel.2010.11.033_bb0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/376775a0","article-title":"Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene","volume":"376","author":"Rogaev","year":"1995","journal-title":"Nature"},{"issue":"8873","key":"10.1016\/j.jconrel.2010.11.033_bb0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0140-6736(93)91705-Q","article-title":"Apolipoprotein E polymorphism and Alzheimer's disease","volume":"342","author":"Poirier","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neurobiolaging.2004.09.003","article-title":"Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease","volume":"26","author":"Poirier","year":"2005","journal-title":"Neurobiol. Aging"},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb0040","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.neurobiolaging.2007.11.003","article-title":"APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease","volume":"30","author":"Barabash","year":"2009","journal-title":"Neurobiol. Aging"},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb0045","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1368-5031.2005.00562.x","article-title":"Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5years","volume":"59","author":"Bullock","year":"2005","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0050","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb0055","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","article-title":"Clinical trial of indomethacin in Alzheimer's disease","volume":"43","author":"Rogers","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer's disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.jconrel.2010.11.033_bb0065","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb0070","first-page":"729","article-title":"Phenserine Axonyx","volume":"6","author":"Thatte","year":"2005","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0404.2006.00685.x","article-title":"Cholesterol as a risk factor for Alzheimer's disease \u2014 epidemiological evidence","volume":"185","author":"Kivipelto","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3233\/JAD-2008-15410","article-title":"The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer's disease: the old, the new and the pilot","volume":"15","author":"Sparks","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2010.11.033_bb0085","doi-asserted-by":"crossref","unstructured":"H. Fillit, Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil. Evid Based Ment Health (2010).","DOI":"10.1136\/ebmh.13.4.117"},{"issue":"23","key":"10.1016\/j.jconrel.2010.11.033_bb0090","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.wad.0000213845.28624.f4","article-title":"A phase 2 study of tramiprosate for cerebral amyloid angiopathy","volume":"20","author":"Greenberg","year":"2006","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J. Nutr. Health Aging"},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12603-009-0047-4","article-title":"Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience","volume":"13","author":"Saumier","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1326-2-17","article-title":"Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau","volume":"2","author":"Santa-Maria","year":"2007","journal-title":"Mol. Neurodegener."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2010.11.033_bb0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2007.09.068","article-title":"Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation","volume":"429","author":"Santa-Maria","year":"2007","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/156720507781077304","article-title":"Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?","volume":"4","author":"Ramassamy","year":"2007","journal-title":"Curr. Alzheimer Res."},{"issue":"19","key":"10.1016\/j.jconrel.2010.11.033_bb0125","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2008.683","article-title":"Ginkgo biloba for prevention of dementia: a randomized controlled trial","volume":"300","author":"DeKosky","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1476-5381.2009.00249.x","article-title":"5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception","volume":"158","author":"Martel","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12603-009-0045-6","article-title":"What we have learned from the Xaliproden Sanofi-aventis trials","volume":"13","author":"Douillet","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0140","doi-asserted-by":"crossref","unstructured":"N. Bassil, P. Thaipisuttikul, G.T. Grossberg, Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease, Expert Opin. Pharmacother. 11(10) (2010) 1765\u20131771.","DOI":"10.1517\/14656566.2010.493874"},{"issue":"10","key":"10.1016\/j.jconrel.2010.11.033_bb0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2165\/11201020-000000000-00000","article-title":"Memantine: a review of its use in moderate to severe Alzheimer's disease","volume":"23","author":"McKeage","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0150","first-page":"367","article-title":"Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias","volume":"4","author":"Thomas","year":"2009","journal-title":"Clin. Interv. Aging"},{"issue":"8000","key":"10.1016\/j.jconrel.2010.11.033_bb0155","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","article-title":"Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue","volume":"34","author":"Perry","year":"1977","journal-title":"J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb0165","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0006-8993(83)90017-3","article-title":"Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease","volume":"289","author":"Rylett","year":"1983","journal-title":"Brain Res."},{"issue":"3\u20134","key":"10.1016\/j.jconrel.2010.11.033_bb0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF01243353","article-title":"Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level","volume":"67","author":"Nilsson","year":"1986","journal-title":"J. Neural Transm."},{"issue":"4537","key":"10.1016\/j.jconrel.2010.11.033_bb0175","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jconrel.2010.11.033_bb0185","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1097\/00001756-200007140-00040","article-title":"Hippocampal acetylcholine release correlates with spatial learning performance in freely moving rats","volume":"11","author":"Fadda","year":"2000","journal-title":"NeuroReport"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1254\/jjp.84.163","article-title":"The scopolamine-induced impairment of spatial cognition parallels the acetylcholine release in the ventral hippocampus in rats","volume":"84","author":"Mishima","year":"2000","journal-title":"Jpn J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cne.902400104","article-title":"An analysis of the origins of the cholinergic and noncholinergic septal projections to the hippocampal formation of the rat","volume":"240","author":"Amaral","year":"1985","journal-title":"J. Comp. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(96)00271-5","article-title":"Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits","volume":"726","author":"Walsh","year":"1996","journal-title":"Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(01)02968-7","article-title":"Differential changes in rat cholinergic parameters subsequent to immunotoxic lesion of the basal forebrain nuclei","volume":"918","author":"Waite","year":"2001","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0210","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0091-3057(94)90267-4","article-title":"Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neurotransmission","volume":"49","author":"Fontana","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","article-title":"Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology","volume":"19","author":"Nordberg","year":"1998","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0220","first-page":"293","article-title":"The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group","volume":"7","author":"Rogers","year":"1996","journal-title":"Dementia"},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb0225","first-page":"27","article-title":"Relative tolerability of Alzheimer's disease treatments","volume":"5","author":"Alva","year":"2008","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0230","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1749-6632.2000.tb06942.x","article-title":"Cholinesterase inhibitors stabilize Alzheimer's disease","volume":"920","author":"Giacobini","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb0235","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1111\/j.1532-5415.2009.02552.x","article-title":"Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey","volume":"57","author":"Seitz","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb0240","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4140\/TCP.n.2004.713","article-title":"Gastrointestinal adverse events in a general population sample of nursing home residents taking cholinesterase inhibitors","volume":"19","author":"Hughes","year":"2004","journal-title":"Consult. Pharm."},{"issue":"17","key":"10.1016\/j.jconrel.2010.11.033_bb0245","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/092986710791111206","article-title":"Tacrine derivatives and Alzheimer's disease","volume":"17","author":"Tumiatti","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"17","key":"10.1016\/j.jconrel.2010.11.033_bb0250","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1021\/jm900859q","article-title":"Pyrano[3, 2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds","volume":"52","author":"Camps","year":"2009","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0255","first-page":"CD001015","article-title":"Lecithin for dementia and cognitive impairment","author":"Higgins","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0260","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0014-2999(92)90392-H","article-title":"L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat","volume":"211","author":"Sigala","year":"1992","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/neu.1997.14.161","article-title":"Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release","volume":"14","author":"Dixon","year":"1997","journal-title":"J. Neurotrauma"},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb0270","first-page":"331","article-title":"A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers","volume":"30","author":"Gatti","year":"1992","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11064-004-9681-8","article-title":"Cytidine 5\u2032-diphosphocholine (CDP-choline) in stroke and other CNS disorders","volume":"30","author":"Adibhatla","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jconrel.2010.11.033_bb0280","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF03188793","article-title":"Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-L-alpha-glycerylphosphorylcholine","volume":"18","author":"Abbiati","year":"1993","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"16","key":"10.1016\/j.jconrel.2010.11.033_bb0285","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0047-6374(01)00310-4","article-title":"Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?","volume":"122","author":"Amenta","year":"2001","journal-title":"Mech. Ageing Dev."},{"issue":"16","key":"10.1016\/j.jconrel.2010.11.033_bb0290","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0047-6374(01)00312-8","article-title":"Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data","volume":"122","author":"Parnetti","year":"2001","journal-title":"Mech. Ageing Dev."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb0295","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jns.2007.01.043","article-title":"Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?","volume":"257","author":"Parnetti","year":"2007","journal-title":"J. Neurol. Sci."},{"issue":"31","key":"10.1016\/j.jconrel.2010.11.033_bb0300","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1523\/JNEUROSCI.1885-08.2008","article-title":"Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory","volume":"28","author":"Wisman","year":"2008","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0305","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2006.04262.x","article-title":"Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis","volume":"100","author":"Millan","year":"2007","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0310","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.npp.1301087","article-title":"Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors","volume":"32","author":"Schilstrom","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0315","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1586\/ern.10.43","article-title":"Combination treatments in Alzheimer's disease: risks and benefits","volume":"10","author":"Sobow","year":"2010","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0320","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0014-5793(00)02076-7","article-title":"Regulation of APP cleavage by alpha-, beta- and gamma-secretases","volume":"483","author":"Nunan","year":"2000","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/REVNEURO.2001.12.1.1","article-title":"The functions of the amyloid precursor protein gene","volume":"12","author":"Panegyres","year":"2001","journal-title":"Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0330","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/S0021-9258(18)53650-4","article-title":"Beta-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms","volume":"268","author":"Haass","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"6618","key":"10.1016\/j.jconrel.2010.11.033_bb0335","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.jconrel.2010.11.033_bb0340","doi-asserted-by":"crossref","first-page":"27765","DOI":"10.1074\/jbc.273.43.27765","article-title":"Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor","volume":"273","author":"Buxbaum","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0345","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/mcne.1999.0811","article-title":"Identification of a novel aspartic protease (Asp 2) as beta-secretase","volume":"14","author":"Hussain","year":"1999","journal-title":"Mol. Cell. Neurosci."},{"issue":"6761","key":"10.1016\/j.jconrel.2010.11.033_bb0350","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/990107","article-title":"Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity","volume":"402","author":"Yan","year":"1999","journal-title":"Nature"},{"issue":"6409","key":"10.1016\/j.jconrel.2010.11.033_bb0355","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/361260a0","article-title":"Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide","volume":"361","author":"Seubert","year":"1993","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.jconrel.2010.11.033_bb0360","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/bi982562p","article-title":"Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease","volume":"38","author":"Wolfe","year":"1999","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0365","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1534-5807(02)00189-2","article-title":"aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation","volume":"3","author":"Francis","year":"2002","journal-title":"Dev. Cell"},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0370","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncb960","article-title":"Reconstitution of gamma-secretase activity","volume":"5","author":"Edbauer","year":"2003","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0375","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jnr.20203","article-title":"Functional reconstitution of gamma-secretase through coordinated expression of presenilin, nicastrin, Aph-1, and Pen-2","volume":"77","author":"Periz","year":"2004","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"De Strooper","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0385","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00023210-200620050-00002","article-title":"Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies","volume":"20","author":"Evin","year":"2006","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/157488906775245354","article-title":"Therapeutic perspectives in Alzheimer's disease","volume":"1","author":"Tschape","year":"2006","journal-title":"Recent Pat. CNS Drug Discov."},{"issue":"29","key":"10.1016\/j.jconrel.2010.11.033_bb0395","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1523\/JNEUROSCI.1026-07.2007","article-title":"The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice","volume":"27","author":"Ring","year":"2007","journal-title":"J. Neurosci."},{"issue":"21","key":"10.1016\/j.jconrel.2010.11.033_bb0400","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/hmg\/11.21.2615","article-title":"The disintegrin\/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts","volume":"11","author":"Hartmann","year":"2002","journal-title":"Hum. Mol. Genet."},{"issue":"50","key":"10.1016\/j.jconrel.2010.11.033_bb0405","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","article-title":"BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions","volume":"25","author":"Laird","year":"2005","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0410","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0896-6273(03)00205-8","article-title":"Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex","volume":"38","author":"De Strooper","year":"2003","journal-title":"Neuron"},{"issue":"6930","key":"10.1016\/j.jconrel.2010.11.033_bb0415","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature01506","article-title":"The role of presenilin cofactors in the gamma-secretase complex","volume":"422","author":"Takasugi","year":"2003","journal-title":"Nature"},{"issue":"6860","key":"10.1016\/j.jconrel.2010.11.033_bb0420","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0425","doi-asserted-by":"crossref","unstructured":"C. Guardia-Laguarta, M. Pera, A. Lleo, gamma-Secretase as a therapeutic target in Alzheimer's disease, Curr Drug Targets 11(4) (2010) 506\u2013517.","DOI":"10.2174\/138945010790980349"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0430","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI200318162","article-title":"NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0435","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0440","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt30","article-title":"A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease","volume":"2","author":"Portelius","year":"2010","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tins.2003.10.008","article-title":"Living with the enemy: a physiological role for the beta-amyloid peptide","volume":"27","author":"Esteban","year":"2004","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0450","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0165-0173(03)00206-6","article-title":"Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply","volume":"43","author":"Atwood","year":"2003","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb0455","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0891-5849(01)00688-8","article-title":"Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease","volume":"31","author":"Kontush","year":"2001","journal-title":"Free Radic. Biol. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb0460","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.freeradbiomed.2006.08.015","article-title":"Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation","volume":"41","author":"Longpre","year":"2006","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0465","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/156720508783954721","article-title":"Processing of amyloid precursor protein and amyloid peptide neurotoxicity","volume":"5","author":"Nathalie","year":"2008","journal-title":"Curr. Alzheimer Res."},{"issue":"36","key":"10.1016\/j.jconrel.2010.11.033_bb0470","doi-asserted-by":"crossref","first-page":"25945","DOI":"10.1074\/jbc.274.36.25945","article-title":"Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates","volume":"274","author":"Walsh","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb0475","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1\u201342 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"20","key":"10.1016\/j.jconrel.2010.11.033_bb0480","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1523\/JNEUROSCI.19-20-08876.1999","article-title":"Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons","volume":"19","author":"Hartley","year":"1999","journal-title":"J. Neurosci."},{"issue":"14","key":"10.1016\/j.jconrel.2010.11.033_bb0485","doi-asserted-by":"crossref","first-page":"10311","DOI":"10.1074\/jbc.M608207200","article-title":"Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct","volume":"282","author":"Necula","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0490","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bbadis.2006.03.002","article-title":"Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease","volume":"1762","author":"Ono","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"13","key":"10.1016\/j.jconrel.2010.11.033_bb0495","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s00018-005-5599-9","article-title":"Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease","volume":"63","author":"Hamaguchi","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb0500","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0006-3223(02)01417-8","article-title":"Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro","volume":"52","author":"Ono","year":"2002","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0505","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1471-4159.2002.00904.x","article-title":"Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro","volume":"81","author":"Ono","year":"2002","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0510","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1248\/bpb.25.375","article-title":"Effect of sucrose on formation of the beta-amyloid fibrils and D-aspartic acids in Abeta 1\u201342","volume":"25","author":"Ueda","year":"2002","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0515","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbadis.2004.06.008","article-title":"Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro","volume":"1690","author":"Ono","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0520","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jnr.20025","article-title":"Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro","volume":"75","author":"Ono","year":"2004","journal-title":"J. Neurosci. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb0525","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.neuropharm.2005.07.004","article-title":"Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro","volume":"49","author":"Hirohata","year":"2005","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0530","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbrc.2005.02.132","article-title":"Preformed beta-amyloid fibrils are destabilized by coenzyme Q(10) in vitro","volume":"330","author":"Ono","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0535","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bbrc.2005.08.148","article-title":"Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro","volume":"336","author":"Ono","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0540","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuint.2005.11.001","article-title":"Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro","volume":"48","author":"Ono","year":"2006","journal-title":"Neurochem. Int."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0545","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbrc.2006.01.063","article-title":"Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro","volume":"341","author":"Ono","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"33","key":"10.1016\/j.jconrel.2010.11.033_bb0550","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.2174\/138161206778793010","article-title":"The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta","volume":"12","author":"Ono","year":"2006","journal-title":"Curr. Pharm. Des."},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb0555","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/bi061540x","article-title":"The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure","volume":"46","author":"Hirohata","year":"2007","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0560","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2007.05.158","article-title":"Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro","volume":"359","author":"Morinaga","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0565","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bmc.2006.09.069","article-title":"Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro","volume":"15","author":"Riviere","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb0570","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/ac702592f","article-title":"Assay to screen for molecules that associate with Alzheimer's related beta-amyloid fibrils","volume":"80","author":"Inbar","year":"2008","journal-title":"Anal. Chem."},{"issue":"47","key":"10.1016\/j.jconrel.2010.11.033_bb0575","doi-asserted-by":"crossref","first-page":"32176","DOI":"10.1074\/jbc.M806154200","article-title":"Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity","volume":"283","author":"Ono","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0580","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.2353\/ajpath.2009.090417","article-title":"Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway","volume":"175","author":"Hamaguchi","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb0585","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0590","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1471-4159.2007.04613.x","article-title":"Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model","volume":"102","author":"Garcia-Alloza","year":"2007","journal-title":"J. Neurochem."},{"issue":"21","key":"10.1016\/j.jconrel.2010.11.033_bb0595","doi-asserted-by":"crossref","first-page":"8370","DOI":"10.1523\/JNEUROSCI.21-21-08370.2001","article-title":"The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse","volume":"21","author":"Lim","year":"2001","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0600","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jconrel.2010.11.033_bb0605","doi-asserted-by":"crossref","unstructured":"J. Bieschke, J. Russ, R.P. Friedrich, D.E. Ehrnhoefer, H. Wobst, K. Neugebauer, E.E. Wanker, EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity, Proc. Natl Acad. Sci. USA 107(17) (2010) 7710\u20137715.","DOI":"10.1073\/pnas.0910723107"},{"issue":"45","key":"10.1016\/j.jconrel.2010.11.033_bb0610","doi-asserted-by":"crossref","first-page":"37377","DOI":"10.1074\/jbc.M508246200","article-title":"Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides","volume":"280","author":"Marambaud","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"38","key":"10.1016\/j.jconrel.2010.11.033_bb0615","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1523\/JNEUROSCI.1521-05.2005","article-title":"Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice","volume":"25","author":"Rezai-Zadeh","year":"2005","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb0620","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.bbapap.2008.08.007","article-title":"Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS","volume":"1784","author":"Shoval","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"13","key":"10.1016\/j.jconrel.2010.11.033_bb0625","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1021\/jf0735073","article-title":"Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms","volume":"56","author":"Singh","year":"2008","journal-title":"J. Agric. Food Chem."},{"issue":"10 Suppl 16","key":"10.1016\/j.jconrel.2010.11.033_bb0630","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S1092852900027061","article-title":"Current state of immunotherapy for Alzheimer's disease","volume":"13","author":"Relkin","year":"2008","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0635","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nm1234","article-title":"Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo","volume":"11","author":"Klyubin","year":"2005","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb0640","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.jconrel.2010.11.033_bb0645","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"5563","key":"10.1016\/j.jconrel.2010.11.033_bb0650","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"issue":"6740","key":"10.1016\/j.jconrel.2010.11.033_bb0655","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.jconrel.2010.11.033_bb0660","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1523\/JNEUROSCI.0381-06.2006","article-title":"Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response","volume":"26","author":"Maier","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2010.11.033_bb0665","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-6632.2000.tb06943.x","article-title":"Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice","volume":"920","author":"Lemere","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"issue":"6815","key":"10.1016\/j.jconrel.2010.11.033_bb0670","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"issue":"6815","key":"10.1016\/j.jconrel.2010.11.033_bb0675","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0680","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb0685","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0690","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jnr.10286","article-title":"Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody","volume":"69","author":"Chauhan","year":"2002","journal-title":"J. Neurosci. Res."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2010.11.033_bb0695","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-2006-102-303","article-title":"Metals and Alzheimer's disease","volume":"10","author":"Adlard","year":"2006","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0700","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-510X(98)00092-6","article-title":"Copper, iron and zinc in Alzheimer's disease senile plaques","volume":"158","author":"Lovell","year":"1998","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0705","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0166-2236(03)00067-5","article-title":"The metallobiology of Alzheimer's disease","volume":"26","author":"Bush","year":"2003","journal-title":"Trends Neurosci."},{"issue":"11\u201312","key":"10.1016\/j.jconrel.2010.11.033_bb0710","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0891-5849(99)00016-7","article-title":"Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?","volume":"26","author":"Castellani","year":"1999","journal-title":"Free Radic. Biol. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2010.11.033_bb0715","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1021\/bi0272151","article-title":"Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence","volume":"42","author":"Dong","year":"2003","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb0720","doi-asserted-by":"crossref","first-page":"RC10","DOI":"10.1523\/JNEUROSCI.19-11-j0002.1999","article-title":"Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice","volume":"19","author":"Lee","year":"1999","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0725","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0006-8993(99)02096-X","article-title":"Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains","volume":"852","author":"Suh","year":"2000","journal-title":"Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb0730","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0006-8993(98)00002-X","article-title":"Abnormal localization of iron regulatory protein in Alzheimer's disease","volume":"788","author":"Smith","year":"1998","journal-title":"Brain Res."},{"issue":"14","key":"10.1016\/j.jconrel.2010.11.033_bb0735","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1523\/JNEUROSCI.0059-07.2007","article-title":"Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP\/PS1 mice without affecting beta-amyloid burden","volume":"27","author":"Malm","year":"2007","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb0740","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.peptides.2005.09.002","article-title":"Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS","volume":"27","author":"Ma","year":"2006","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb0745","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.peptides.2007.08.022","article-title":"Copper (II) modulates in vitro aggregation of a tau peptide","volume":"28","author":"Zhou","year":"2007","journal-title":"Peptides"},{"issue":"47","key":"10.1016\/j.jconrel.2010.11.033_bb0750","doi-asserted-by":"crossref","first-page":"45518","DOI":"10.1074\/jbc.M207435200","article-title":"An iron-responsive element type II in the 5\u2032-untranslated region of the Alzheimer's amyloid precursor protein transcript","volume":"277","author":"Rogers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2010.11.033_bb0755","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1332.003","article-title":"The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5\u2032-untranslated region","volume":"1035","author":"Venti","year":"2004","journal-title":"Ann. NY Acad. Sci."},{"issue":"16","key":"10.1016\/j.jconrel.2010.11.033_bb0760","doi-asserted-by":"crossref","first-page":"12152","DOI":"10.1016\/S0021-9258(17)32694-7","article-title":"Modulation of A beta adhesiveness and secretase site cleavage by zinc","volume":"269","author":"Bush","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"5177","key":"10.1016\/j.jconrel.2010.11.033_bb0765","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.8073293","article-title":"Rapid induction of Alzheimer A beta amyloid formation by zinc","volume":"265","author":"Bush","year":"1994","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0770","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1471-4159.2000.0751219.x","article-title":"Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1\u201342","volume":"75","author":"Atwood","year":"2000","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0775","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbapap.2005.09.012","article-title":"Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease","volume":"1764","author":"Syme","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0780","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-4658.2006.05563.x","article-title":"High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide","volume":"274","author":"Danielsson","year":"2007","journal-title":"FEBS J."},{"issue":"43","key":"10.1016\/j.jconrel.2010.11.033_bb0785","doi-asserted-by":"crossref","first-page":"40302","DOI":"10.1074\/jbc.M206428200","article-title":"Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2)","volume":"277","author":"Opazo","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0790","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/psc.626","article-title":"Methionine regulates copper\/hydrogen peroxide oxidation products of Abeta","volume":"11","author":"Ali","year":"2005","journal-title":"J. Pept. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb0795","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1096\/fj.04-1890fje","article-title":"Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid","volume":"18","author":"Barnham","year":"2004","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb0800","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00775-004-0602-8","article-title":"Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides","volume":"9","author":"Huang","year":"2004","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.jconrel.2010.11.033_bb0805","doi-asserted-by":"crossref","unstructured":"M.A. Smith, X. Zhu, M. Tabaton, G. Liu, D.W. McKeel, Jr., M.L. Cohen, X. Wang, S.L. Siedlak, B.E. Dwyer, T. Hayashi, M. Nakamura, A. Nunomura, G. Perry, Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment, J. Alzheimers Dis. 19(1) (2010) 363\u2013372.","DOI":"10.3233\/JAD-2010-1239"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0810","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1749-6632.1965.tb54077.x","article-title":"The biochemistry of desferrioxamine and its relation to iron metabolism","volume":"119","author":"Keberle","year":"1964","journal-title":"Ann. NY Acad. Sci."},{"issue":"8753","key":"10.1016\/j.jconrel.2010.11.033_bb0815","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","article-title":"Intramuscular desferrioxamine in patients with Alzheimer's disease","volume":"337","author":"Crapper McLachlan","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2010.11.033_bb0820","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.2000.tb06938.x","article-title":"Metal chelation as a potential therapy for Alzheimer's disease","volume":"920","author":"Cuajungco","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0825","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper\u2013zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0830","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1046\/j.1471-4159.1999.0720734.x","article-title":"F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease","volume":"72","author":"Nourooz-Zadeh","year":"1999","journal-title":"J. Neurochem."},{"issue":"5\u20136","key":"10.1016\/j.jconrel.2010.11.033_bb0835","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0891-5849(99)00102-1","article-title":"Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype","volume":"27","author":"Ramassamy","year":"1999","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0840","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1006\/nbdi.1999.0273","article-title":"Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain","volume":"7","author":"Ramassamy","year":"2000","journal-title":"Neurobiol. Dis."},{"issue":"6587","key":"10.1016\/j.jconrel.2010.11.033_bb0845","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/382120b0","article-title":"Oxidative damage in Alzheimer's","volume":"382","author":"Smith","year":"1996","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0850","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9","article-title":"Increased 8, 12-iso-iPF(2 alpha)-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity","volume":"48","author":"Pratico","year":"2000","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0855","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1874467211003020066","article-title":"Potential role of acrolein in neurodegeneration and in Alzheimer's disease","volume":"3","author":"Nam","year":"2010","journal-title":"Curr. Mol. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb0860","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1523\/JNEUROSCI.21-12-04183.2001","article-title":"Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis","volume":"21","author":"Pratico","year":"2001","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0865","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0197-4580(02)00225-7","article-title":"Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1\u201342) in a transgenic Caenorhabditis elegans model","volume":"24","author":"Drake","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0870","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2004.09.003","article-title":"Impaired Cu\/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice","volume":"18","author":"Schuessel","year":"2005","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb0875","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.freeradbiomed.2008.03.012","article-title":"Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease","volume":"44","author":"Resende","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0880","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.freeradbiomed.2008.04.022","article-title":"Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models","volume":"45","author":"Sonnen","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"40","key":"10.1016\/j.jconrel.2010.11.033_bb0885","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1523\/JNEUROSCI.3040-05.2005","article-title":"Ribosome dysfunction is an early event in Alzheimer's disease","volume":"25","author":"Ding","year":"2005","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb0890","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/01.WNL.0000156156.13641.BA","article-title":"Evidence of increased oxidative damage in subjects with mild cognitive impairment","volume":"64","author":"Keller","year":"2005","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0895","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archneur.59.6.972","article-title":"Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease","volume":"59","author":"Pratico","year":"2002","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0900","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neurobiolaging.2004.07.016","article-title":"Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients","volume":"26","author":"Migliore","year":"2005","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0905","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neurobiolaging.2005.01.016","article-title":"Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment","volume":"27","author":"Schipper","year":"2006","journal-title":"Neurobiol. Aging"},{"issue":"23","key":"10.1016\/j.jconrel.2010.11.033_bb0910","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1021\/bi000169p","article-title":"Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells","volume":"39","author":"Misonou","year":"2000","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0915","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1006\/bbrc.2000.2164","article-title":"Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells","volume":"268","author":"Paola","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0920","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/jnr.10525","article-title":"Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells","volume":"71","author":"Gomez-Ramos","year":"2003","journal-title":"J. Neurosci. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb0925","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0891-5849(02)01021-3","article-title":"Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain","volume":"33","author":"Smith","year":"2002","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0930","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1471-4159.2004.02455.x","article-title":"Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice","volume":"89","author":"Li","year":"2004","journal-title":"J. Neurochem."},{"issue":"13","key":"10.1016\/j.jconrel.2010.11.033_bb0935","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1021\/jf0735073","article-title":"Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms","volume":"56","author":"Singh","year":"2008","journal-title":"J. Agric. Food Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb0940","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0091-7435(92)90041-F","article-title":"Green tea composition, consumption, and polyphenol chemistry","volume":"21","author":"Graham","year":"1992","journal-title":"Prev. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0945","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1753-4887.2004.tb00041.x","article-title":"Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials","volume":"62","author":"Moyers","year":"2004","journal-title":"Nutr. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0950","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0304-4165(98)00168-8","article-title":"ESR study on the structure\u2013antioxidant activity relationship of tea catechins and their epimers","volume":"1427","author":"Guo","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb0955","first-page":"BR166","article-title":"Protective effects of green tea catechins on cerebral ischemic damage","volume":"10","author":"Suzuki","year":"2004","journal-title":"Med. Sci. Monit."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb0960","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1096\/fj.04-2806fje","article-title":"Neuroprotective effects of (\u2212)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action","volume":"19","author":"Sutherland","year":"2005","journal-title":"FASEB J."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb0965","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000085385","article-title":"Multifunctional activities of green tea catechins in neuroprotection \u2014 modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway","volume":"14","author":"Mandel","year":"2005","journal-title":"Neurosignals"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0970","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1460-9568.2005.04532.x","article-title":"Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity","volume":"23","author":"Bastianetto","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb0975","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0024-3205(01)01438-2","article-title":"The green tea polyphenol (\u2212)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons","volume":"70","author":"Choi","year":"2001","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb0980","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1096\/fj.02-0881fje","article-title":"Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (\u2212)-epigallocatechin-3-gallate","volume":"17","author":"Levites","year":"2003","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb0985","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1471-4159.2003.01976.x","article-title":"Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease","volume":"87","author":"Ono","year":"2003","journal-title":"J. Neurochem."},{"issue":"5535","key":"10.1016\/j.jconrel.2010.11.033_bb0990","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1062374","article-title":"Duration of nuclear NF-kappaB action regulated by reversible acetylation","volume":"293","author":"Chen","year":"2001","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb0995","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molbrainres.2003.07.003","article-title":"Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase\/Akt and glycogen synthase kinase-3","volume":"118","author":"Koh","year":"2003","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"34","key":"10.1016\/j.jconrel.2010.11.033_bb1000","doi-asserted-by":"crossref","first-page":"30574","DOI":"10.1074\/jbc.M202832200","article-title":"Involvement of protein kinase C activation and cell survival\/cell cycle genes in green tea polyphenol (\u2212)-epigallocatechin 3-gallate neuroprotective action","volume":"277","author":"Levites","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb1005","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1523\/JNEUROSCI.21-09-02929.2001","article-title":"How protein kinase C activation protects nerve cells from oxidative stress-induced cell death","volume":"21","author":"Maher","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.foodchem.2010.03.027","article-title":"Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution","volume":"122","author":"Dube","year":"2010","journal-title":"Food Chem."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb1015","first-page":"3312","article-title":"Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals","volume":"9","author":"Chow","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1020","first-page":"1","article-title":"Plasma appearance and correlation between coffee and green tea metabolites in human subjects","author":"Renouf","year":"2010","journal-title":"Br. J. Nutr."},{"issue":"1A","key":"10.1016\/j.jconrel.2010.11.033_bb1025","first-page":"363","article-title":"Anticancer potential of curcumin: preclinical and clinical studies","volume":"23","author":"Aggarwal","year":"2003","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/glia.20306","article-title":"Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration","volume":"53","author":"Craft","year":"2006","journal-title":"Glia"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2010.11.033_bb1035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijdevneu.2005.11.001","article-title":"Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology","volume":"24","author":"Hoozemans","year":"2006","journal-title":"Int. J. Dev. Neurosci."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3233\/JAD-2004-6403","article-title":"Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models","volume":"6","author":"Baum","year":"2004","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb1045","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0773.1978.tb02240.x","article-title":"A study on the fate of curcumin in the rat","volume":"43","author":"Wahlstrom","year":"1978","journal-title":"Acta Pharmacol. Toxicol. (Copenh.)"},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-2006-957450","article-title":"Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers","volume":"64","author":"Shoba","year":"1998","journal-title":"Planta Med."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jchromb.2007.03.010","article-title":"Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS\/MS","volume":"853","author":"Yang","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0300-483X(81)90027-5","article-title":"Metabolism of curcumin\u2014studies with [3H]curcumin","volume":"22","author":"Ravindranath","year":"1981","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1070","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0090-9556(24)15211-7","article-title":"Biotransformation of curcumin through reduction and glucuronidation in mice","volume":"27","author":"Pan","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0009-9120(96)00155-5","article-title":"Resveratrol: a molecule whose time has come? And gone?","volume":"30","author":"Soleas","year":"1997","journal-title":"Clin. Biochem."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/aje\/kwf074","article-title":"Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging","volume":"156","author":"Lindsay","year":"2002","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1085","first-page":"185","article-title":"Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area","volume":"153","author":"Orgogozo","year":"1997","journal-title":"Rev. Neurol. (Paris)"},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb1090","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/01.WNL.0000031421.50369.E7","article-title":"Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study","volume":"59","author":"Truelsen","year":"2002","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb1095","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0891-5849(03)00062-5","article-title":"Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death","volume":"34","author":"Jang","year":"2003","journal-title":"Free Radic. Biol. Med."},{"issue":"17","key":"10.1016\/j.jconrel.2010.11.033_bb1100","doi-asserted-by":"crossref","first-page":"17038","DOI":"10.1074\/jbc.M500655200","article-title":"Substrate-specific activation of sirtuins by resveratrol","volume":"280","author":"Kaeberlein","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"7117","key":"10.1016\/j.jconrel.2010.11.033_bb1105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature05354","article-title":"Resveratrol improves health and survival of mice on a high-calorie diet","volume":"444","author":"Baur","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1110","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bbrc.2005.03.237","article-title":"Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells","volume":"331","author":"Chen","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"19","key":"10.1016\/j.jconrel.2010.11.033_bb1115","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.febslet.2010.09.022","article-title":"EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP","volume":"584","author":"Fernandez","year":"2010","journal-title":"FEBS Lett."},{"issue":"22","key":"10.1016\/j.jconrel.2010.11.033_bb1120","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1016\/j.bmcl.2003.09.018","article-title":"Green tea catechins as a BACE1 (beta-secretase) inhibitor","volume":"13","author":"Jeon","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"37","key":"10.1016\/j.jconrel.2010.11.033_bb1125","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/bi100939a","article-title":"The flavanol (\u2212)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity","volume":"49","author":"Meng","year":"2010","journal-title":"Biochemistry"},{"issue":"17","key":"10.1016\/j.jconrel.2010.11.033_bb1130","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neulet.2010.08.035","article-title":"The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells","volume":"485","author":"Liu","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb1140","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0197-4580(01)00300-1","article-title":"Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology","volume":"22","author":"Frautschy","year":"2001","journal-title":"Neurobiol. Aging"},{"issue":"31","key":"10.1016\/j.jconrel.2010.11.033_bb1145","doi-asserted-by":"crossref","first-page":"24228","DOI":"10.1074\/jbc.M110.133108","article-title":"Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers","volume":"285","author":"Ladiwala","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3940(01)01677-9","article-title":"Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1\u201342) insult","volume":"303","author":"Kim","year":"2001","journal-title":"Neurosci. Lett."},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb1155","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0891-5849(03)00062-5","article-title":"Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death","volume":"34","author":"Jang","year":"2003","journal-title":"Free Radic. Biol. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb1160","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000073766","article-title":"Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity","volume":"49","author":"Savaskan","year":"2003","journal-title":"Gerontology"},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb1165","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bjp.0705688","article-title":"Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C","volume":"141","author":"Han","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb1170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jnutbio.2006.11.001","article-title":"Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells","volume":"18","author":"Kim","year":"2007","journal-title":"J. Nutr. Biochem."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1175","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1471-4159.2004.02800.x","article-title":"Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor","volume":"91","author":"Giri","year":"2004","journal-title":"J. Neurochem."},{"issue":"21","key":"10.1016\/j.jconrel.2010.11.033_bb1180","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0024-3205(02)02083-0","article-title":"Chronic treatment with trans rosveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats","volume":"71","author":"Sharma","year":"2002","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000097511","article-title":"Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats","volume":"79","author":"Kumar","year":"2007","journal-title":"Pharmacology"},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb1190","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jnutbio.2007.08.008","article-title":"Green tea catechins prevent cognitive deficits caused by Abeta1\u201340 in rats","volume":"19","author":"Haque","year":"2008","journal-title":"J. Nutr. Biochem."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb1195","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.euroneuro.2009.02.002","article-title":"Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT)","volume":"19","author":"Ishrat","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"21","key":"10.1016\/j.jconrel.2010.11.033_bb1200","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0024-3205(02)02083-0","article-title":"Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats","volume":"71","author":"Sharma","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1205","doi-asserted-by":"crossref","DOI":"10.1002\/med.20201","article-title":"Nanoparticulate devices for brain drug delivery","author":"Celia","year":"2010","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/A:1006995910836","article-title":"Tight junctions of the blood-brain barrier","volume":"20","author":"Kniesel","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb1215","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0166-2236(00)02004-X","article-title":"Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier","volume":"24","author":"Huber","year":"2001","journal-title":"Trends Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1220","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb1225","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/10611869609015962","article-title":"Modulation of blood-brain barrier permeability","volume":"3","author":"Rapoport","year":"1996","journal-title":"J. Drug Target."},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb1230","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1023\/A:1015884603456","article-title":"Delivering peptides to the central nervous system: dilemmas and strategies","volume":"8","author":"Banks","year":"1991","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1235","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1240","first-page":"39","article-title":"Control of brain endothelial permeability","volume":"3","author":"Abbott","year":"1991","journal-title":"Cerebrovasc. Brain Metab. Rev."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2010.11.033_bb1245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2005.07.024","article-title":"Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease","volume":"108","author":"Roney","year":"2005","journal-title":"J. Control. Release"},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2010.11.033_bb1250","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0168-3659(01)00342-X","article-title":"Tumour targeted delivery of encapsulated dextran\u2013doxorubicin conjugate using chitosan nanoparticles as carrier","volume":"74","author":"Mitra","year":"2001","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nano.2007.11.004","article-title":"Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery","volume":"4","author":"Jain","year":"2008","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0939-6411(99)00073-9","article-title":"Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system","volume":"49","author":"Friese","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1265","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2008.03.009","article-title":"Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles","volume":"70","author":"Wilson","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nano.2009.04.001","article-title":"Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine","volume":"6","author":"Wilson","year":"2009","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb1275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0167-7799(97)01036-6","article-title":"Biomedical applications of nanotechnology\u2014implications for drug targeting and gene therapy","volume":"15","author":"Davis","year":"1997","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1280","series-title":"Microspheres and Drug Therapy, Pharmaceutical, Immunological and Medical Aspects","first-page":"1","article-title":"Structural elements determining transport and exchange process in the liver","author":"Wisse","year":"1984"},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb1285","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1023\/A:1018970030327","article-title":"In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure","volume":"10","author":"Allemann","year":"1993","journal-title":"Pharm. Res."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-5173(02)00267-3","article-title":"Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles","volume":"243","author":"Banerjee","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1295","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.jconrel.2010.11.033_bb1300","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1359-0286(02)00117-1","article-title":"Biodegradable nanoparticles for drug delivery and targeting","volume":"6","author":"Hans","year":"2002","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","article-title":"Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease","volume":"1200","author":"Wilson","year":"2008","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future","volume":"47","author":"Muller","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1315","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jconrel.2003.08.006","article-title":"Brain uptake of thiamine-coated nanoparticles","volume":"93","author":"Lockman","year":"2003","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1320","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/A:1023492015851","article-title":"In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles","volume":"20","author":"Lockman","year":"2003","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb1325","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1023\/B:PHAM.0000003374.58641.62","article-title":"In situ blood-brain barrier transport of nanoparticles","volume":"20","author":"Koziara","year":"2003","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb1330","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.bmc.2009.02.043","article-title":"Nanoparticles in cellular drug delivery","volume":"17","author":"Faraji","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1335","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpb.2004.07.009","article-title":"Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases","volume":"59","author":"Cui","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1340","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2009.03.064","article-title":"Nanoparticle\u2013chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease","volume":"455","author":"Liu","year":"2009","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/wnan.59","article-title":"Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease","volume":"2","author":"Kulkarni","year":"2010","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1350","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.nano.2009.04.001","article-title":"Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine","volume":"6","author":"Wilson","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1355","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","article-title":"Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease","volume":"1200","author":"Wilson","year":"2008","journal-title":"Brain Res."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2010.11.033_bb1360","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijdevneu.2005.11.012","article-title":"Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP\/PS1 transgenic mice","volume":"24","author":"Siegemund","year":"2006","journal-title":"Int. J. Dev. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1365","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijpharm.2010.01.012","article-title":"Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease","volume":"389","author":"Smith","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1370","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","article-title":"Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain","volume":"31","author":"Wang","year":"2010","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1375","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1208\/s12249-009-9279-1","article-title":"Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB","volume":"10","author":"Songjiang","year":"2009","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1380","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/mp900306x","article-title":"ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model","volume":"7","author":"Mulik","year":"2010","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1385","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2009.03.002","article-title":"Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones","volume":"137","author":"Zensi","year":"2009","journal-title":"J. Control. Release"},{"issue":"5\u20138","key":"10.1016\/j.jconrel.2010.11.033_bb1390","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.msec.2006.08.003","article-title":"Gold nanoparticles for selective and remote heating of beta-amyloid protein aggregates","volume":"27","author":"Bastus","year":"2007","journal-title":"Mater. Sci. Eng. C Biomim. Supramol. Syst."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1395","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.bbrc.2009.06.110","article-title":"Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field","volume":"386","author":"Skaat","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1400","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejpb.2008.07.005","article-title":"Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting","volume":"70","author":"Wang","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1405","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejpb.2007.11.010","article-title":"Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver","volume":"69","author":"Schaffazick","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2004.11.003","article-title":"Protective properties of melatonin-loaded nanoparticles against lipid peroxidation","volume":"289","author":"Schaffazick","year":"2005","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1415","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","article-title":"Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration","volume":"121","author":"Gao","year":"2007","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1420","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbadis.2005.06.006","article-title":"Nanoparticle and other metal chelation therapeutics in Alzheimer disease","volume":"1741","author":"Liu","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1425","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jn\/122.2.355","article-title":"Penicillamine: pharmacokinetics and differential effects on zinc and copper status in chicks","volume":"122","author":"Lu","year":"1992","journal-title":"J. Nutr."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1430","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neulet.2006.07.020","article-title":"Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance","volume":"406","author":"Liu","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1435","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","article-title":"Nanoparticulate systems for brain delivery of drugs","volume":"47","author":"Kreuter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1440","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J. Drug Target."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1445","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.138.4.877","article-title":"A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier","volume":"138","author":"Dehouck","year":"1997","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb1450","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/03639049809089942","article-title":"Chitosan: a unique polysaccharide for drug delivery","volume":"24","author":"Felt","year":"1998","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb1455","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0142-9612(94)90209-7","article-title":"Incorporation of basic fibroblast growth factor into methylpyrrolidinone chitosan fleeces and determination of the in vitro release characteristics","volume":"15","author":"Berscht","year":"1994","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.jconrel.2010.11.033_bb1460","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0024-3205(01)01232-2","article-title":"Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain","volume":"69","author":"Klunk","year":"2001","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1465","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0304-3940(02)01399-X","article-title":"Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer's disease","volume":"338","author":"Hartig","year":"2003","journal-title":"Neurosci. Lett."},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb1470","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1007\/s11095-008-9688-y","article-title":"Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy","volume":"25","author":"Agyare","year":"2008","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1475","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1480","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1460-9568.2009.07038.x","article-title":"In vivo labelling of hippocampal beta-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles","volume":"31","author":"Hartig","year":"2010","journal-title":"Eur. J. Neurosci."},{"issue":"19","key":"10.1016\/j.jconrel.2010.11.033_bb1485","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1039\/b909612d","article-title":"A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques","volume":"7","author":"Elsinghorst","year":"2009","journal-title":"Org. Biomol. Chem."},{"issue":"9","key":"10.1016\/j.jconrel.2010.11.033_bb1490","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1021\/nn900813b","article-title":"Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle","volume":"3","author":"Neely","year":"2009","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1495","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1208\/pt030105","article-title":"Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs","volume":"3","author":"Al-Ghananeem","year":"2002","journal-title":"AAPS PharmSciTech"},{"issue":"14","key":"10.1016\/j.jconrel.2010.11.033_bb1500","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S1359-6446(02)02332-2","article-title":"Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease","volume":"7","author":"Bodor","year":"2002","journal-title":"Drug Discov. Today"},{"issue":"18","key":"10.1016\/j.jconrel.2010.11.033_bb1505","doi-asserted-by":"crossref","first-page":"13065","DOI":"10.1016\/S0021-9258(17)36796-0","article-title":"Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein","volume":"269","author":"Jaffe","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1510","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JAD-2008-15406","article-title":"Estrogen and hippocampal plasticity in rodent models","volume":"15","author":"Foy","year":"2008","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1515","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0006-8993(94)91694-2","article-title":"Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague\u2013Dawley rats","volume":"644","author":"Singh","year":"1994","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1520","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00737-002-0005-1","article-title":"Neuroprotective effects of estradiol-17beta: implications for psychiatric disorders","volume":"5","author":"Kolsch","year":"2002","journal-title":"Arch. Womens Ment. Health"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1525","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0306-4522(00)00410-3","article-title":"The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis","volume":"101","author":"Hogervorst","year":"2000","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb1530","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jama.285.11.1489","article-title":"Hormone replacement therapy and cognition: systematic review and meta-analysis","volume":"285","author":"LeBlanc","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1535","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1521-690X(02)00082-9","article-title":"The menopause and HRT. HRT and cognitive decline","volume":"17","author":"Maki","year":"2003","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"14","key":"10.1016\/j.jconrel.2010.11.033_bb1540","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1545","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jama.288.3.366","article-title":"Failure of estrogen plus progestin therapy for prevention","volume":"288","author":"Fletcher","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1550","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1555","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2007.01.016","article-title":"Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo","volume":"119","author":"Mittal","year":"2007","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1560","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1521-690X(03)00016-2","article-title":"Melatonin: clinical relevance","volume":"17","author":"Reiter","year":"2003","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"25","key":"10.1016\/j.jconrel.2010.11.033_bb1565","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0024-3205(97)00030-1","article-title":"Pharmacological actions of melatonin in oxygen radical pathophysiology","volume":"60","author":"Reiter","year":"1997","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1570","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0301-0082(98)00052-5","article-title":"Oxidative damage in the central nervous system: protection by melatonin","volume":"56","author":"Reiter","year":"1998","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1575","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1521-690X(03)00016-2","article-title":"Melatonin: clinical relevance","volume":"17","author":"Reiter","year":"2003","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1580","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.biocel.2005.08.020","article-title":"Melatonin","volume":"38","author":"Hardeland","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1585","doi-asserted-by":"crossref","unstructured":"X. Yang, Y. Yang, Z. Fu, Y. Li, J. Feng, J. Luo, Q. Zhang, Q. Wang, Q. Tian, Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol (2010).","DOI":"10.1177\/0269881110367723"},{"issue":"8","key":"10.1016\/j.jconrel.2010.11.033_bb1590","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0047-6374(01)00384-0","article-title":"Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin","volume":"123","author":"Reiter","year":"2002","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1595","first-page":"395","article-title":"Alzheimer's disease and melatonin","volume":"1252","author":"Matsubara","year":"2003","journal-title":"Mol. Mech. Epochal Ther. Ischemic Stroke Dement."},{"issue":"951","key":"10.1016\/j.jconrel.2010.11.033_bb1600","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.169.3951.1217","article-title":"Polypeptide with broad biological activity: isolation from small intestine","volume":"169","author":"Said","year":"1970","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1605","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000198339","article-title":"Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function","volume":"19","author":"Fahrenkrug","year":"1979","journal-title":"Digestion"},{"key":"10.1016\/j.jconrel.2010.11.033_bb1610","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.1998.tb11180.x","article-title":"VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide","volume":"865","author":"Brenneman","year":"1998","journal-title":"Ann. NY Acad. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0006-8993(97)00218-7","article-title":"Co-localization of vasoactive intestinal polypeptide, gamma-aminobutyric acid and choline acetyltransferase in neocortical interneurons of the adult rat","volume":"757","author":"Bayraktar","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1620","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1999.tb07884.x","article-title":"A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein","volume":"897","author":"Gozes","year":"1999","journal-title":"Ann. NY Acad. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2010.11.033_bb1625","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/glia.20681","article-title":"Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels","volume":"56","author":"Delgado","year":"2008","journal-title":"Glia"},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb1630","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0891-5849(95)02227-9","article-title":"Structure\u2013antioxidant activity relationships of flavonoids and phenolic acids","volume":"20","author":"Rice-Evans","year":"1996","journal-title":"Free Radic. Biol. Med."},{"issue":"8S Suppl","key":"10.1016\/j.jconrel.2010.11.033_bb1635","doi-asserted-by":"crossref","first-page":"2073S","DOI":"10.1093\/jn\/130.8.2073S","article-title":"Dietary intake and bioavailability of polyphenols","volume":"130","author":"Scalbert","year":"2000","journal-title":"J. Nutr."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1640","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0891-5849(02)00877-8","article-title":"The metabolic fate of dietary polyphenols in humans","volume":"33","author":"Rechner","year":"2002","journal-title":"Free Radic. Biol. Med."},{"issue":"10 Pt 1","key":"10.1016\/j.jconrel.2010.11.033_bb1645","first-page":"1025","article-title":"Pharmacokinetics of tea catechins after ingestion of green tea and (\u2212)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability","volume":"11","author":"Lee","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1650","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0891-5849(02)00911-5","article-title":"Inhibition of cancer growth by resveratrol is related to its low bioavailability","volume":"33","author":"Asensi","year":"2002","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1655","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/jpet.102.033340","article-title":"Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model","volume":"302","author":"Marier","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb1660","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1124\/dmd.104.000885","article-title":"High absorption but very low bioavailability of oral resveratrol in humans","volume":"32","author":"Walle","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1665","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.brainres.2008.02.107","article-title":"Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice","volume":"1214","author":"Rezai-Zadeh","year":"2008","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.jconrel.2010.11.033_bb1670","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2174\/138920006778520552","article-title":"Metabolism of green tea catechins: an overview","volume":"7","author":"Feng","year":"2006","journal-title":"Curr. Drug Metab."},{"issue":"11","key":"10.1016\/j.jconrel.2010.11.033_bb1675","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.30.11.1246","article-title":"Contribution of presystemic hepatic extraction to the low oral bioavailability of green tea catechins in rats","volume":"30","author":"Cai","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1680","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejps.2010.06.010","article-title":"Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (\u2212)-epigallocatechin gallate","volume":"41","author":"Dube","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1685","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1046\/j.1471-4159.1997.69051995.x","article-title":"Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta","volume":"69","author":"Martel","year":"1997","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1690","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng0996-55","article-title":"Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides","volume":"14","author":"Miyata","year":"1996","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.jconrel.2010.11.033_bb1695","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1046\/j.1471-4159.1998.70041458.x","article-title":"Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons","volume":"70","author":"Beffert","year":"1998","journal-title":"J. Neurochem."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1700","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0006-8993(99)01894-6","article-title":"Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent","volume":"843","author":"Beffert","year":"1999","journal-title":"Brain Res."},{"issue":"12","key":"10.1016\/j.jconrel.2010.11.033_bb1705","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1517\/13543784.16.12.1921","article-title":"Natural antioxidants in Alzheimer's disease","volume":"16","author":"Mancuso","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.jconrel.2010.11.033_bb1710","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.taap.2006.12.025","article-title":"Resveratrol: a review of preclinical studies for human cancer prevention","volume":"224","author":"Athar","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1715","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.brainresrev.2006.04.004","article-title":"Resveratrol \u2014 a boon for treating Alzheimer's disease?","volume":"52","author":"Anekonda","year":"2006","journal-title":"Brain Res. Rev."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1720","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2009.03.021","article-title":"Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress","volume":"375","author":"Lu","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2010.11.033_bb1725","doi-asserted-by":"crossref","unstructured":"J. Ali, M. Ali, S. Baboota, J.K. Sahni, C. Ramassamy, L. Dao, Bhavna, Potential of nanoparticulate drug delivery systems by intranasal administration, Curr. Pharm. Des. 16(14) (2010) 1644\u20131653.","DOI":"10.2174\/138161210791164108"},{"issue":"1","key":"10.1016\/j.jconrel.2010.11.033_bb1730","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2010.11.033_bb1735","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2008.06.035","article-title":"TiO2 nanoparticles promote beta-amyloid fibrillation in vitro","volume":"373","author":"Wu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"31","key":"10.1016\/j.jconrel.2010.11.033_bb1740","doi-asserted-by":"crossref","first-page":"8043","DOI":"10.1016\/j.biomaterials.2010.07.011","article-title":"Neurotoxicological effects and the impairment of spatial recognition memory in mice caused by exposure to TiO2 nanoparticles","volume":"31","author":"Hu","year":"2010","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.jconrel.2010.11.033_bb1745","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2217\/17435889.2.6.753","article-title":"Nanoneuroscience: emerging concepts on nanoneurotoxicity and nanoneuroprotection","volume":"2","author":"Sharma","year":"2007","journal-title":"Nanomed"},{"issue":"5","key":"10.1016\/j.jconrel.2010.11.033_bb1750","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjp.0707130","article-title":"Nanoparticles: pharmacological and toxicological significance","volume":"150","author":"Medina","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2010.11.033_bb1755","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2010.04.026","article-title":"Potential neurotoxicity of nanoparticles","volume":"394","author":"Hu","year":"2010","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365910009612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365910009612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:23:18Z","timestamp":1740748998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365910009612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":351,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0168365910009612"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2010.11.033","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}